AI in myeloproliferative neoplasms can grade marrow fibrosis and predict survival, but authors say prospective, outcome-focused trials are needed first.

Costs of multimorbidity in older adults are climbing faster than its disability toll, and study authors say policy should look past single-disease programs.

October's FDA approvals included the introduction of 5 non-oncology treatment options across specialties.

PBM reform, Medicare Advantage exits, and the 340B rebate pilot are reshaping drug access. Here is what payers need to know heading into 2027.

Bipolar disorder often goes undiagnosed for years, and clinicians need to separate mood episodes from normal emotions and keep patients on treatment.

A phase 4 study found 69% of patients with OAB were consistently satisfied with vibegron at 12 months, with exploratory persistence of 59.8%.

Two machine learning models identifies MASLD in lean adults using 8 routine clinical measurements.

Weekly gefurulimab cut MG-ADL scores by 4.2 points vs 2.6 with placebo at week 26 in adults with generalized myasthenia gravis in the PREVAIL study.